CIDP
MCID: CHR283
MIFTS: 52

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Categories: Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 38 76 53 54 59
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 53 59
Cidp 53 59
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 73

Characteristics:

Orphanet epidemiological data:

59
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA2932
UMLS via Orphanet 74 C0393819
ICD10 via Orphanet 34 G61.8
UMLS 73 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

NIH Rare Diseases : 53 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physical therapy, and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence.

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to polyneuropathy and demyelinating polyneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is CNTN2 (Contactin 2), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and L1CAM interactions. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and spinal cord, and related phenotypes are falls and paresthesia

NINDS : 54 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia : 76 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 polyneuropathy 32.0 IFNA2 TTR
2 demyelinating polyneuropathy 31.0 AIF1 CNTN2 HP NFASC TTR
3 peripheral nervous system disease 29.5 NFASC TTR
4 chronic inflammatory demyelinating polyradiculoneuropathy 12.8
5 lewis-sumner syndrome 11.6
6 chronic inflammatory demyelinating polyneuritis 11.5
7 x-linked charcot-marie-tooth disease 11.4
8 polyradiculoneuropathy 11.3
9 guillain-barre syndrome, familial 11.1
10 neuropathy 10.7
11 hepatitis 10.4
12 diabetes mellitus 10.4
13 myasthenia gravis 10.4
14 charcot-marie-tooth disease 10.4
15 tooth disease 10.4
16 myasthenia gravis congenital 10.4
17 multiple sclerosis 10.3
18 multifocal motor neuropathy 10.3
19 lymphoma 10.3
20 poems syndrome 10.3
21 melanoma 10.3
22 hepatitis b 10.3
23 lupus erythematosus 10.3
24 systemic lupus erythematosus 10.2
25 glomerulonephritis 10.2
26 respiratory failure 10.2
27 guillain-barre syndrome 10.2
28 hepatitis c 10.2
29 psoriasis 10.2
30 viral infectious disease 10.2
31 carpal tunnel syndrome 10.1
32 focal segmental glomerulosclerosis 1 10.1
33 hepatitis c virus 10.1
34 mononeuropathy of the median nerve, mild 10.1
35 membranous nephropathy 10.1
36 arthritis 10.1
37 crohn's disease 10.1
38 diabetic neuropathy 10.1
39 focal segmental glomerulosclerosis 10.1
40 scoliosis 10.1
41 abducens nerve disease 10.1
42 diabetic polyneuropathy 10.1
43 mononeuritis multiplex 10.1
44 sensory peripheral neuropathy 10.1
45 myopathy 10.1
46 intracranial hypertension 10.1
47 amyloid neuropathy 10.1
48 autoimmune disease 10.1
49 osteoporosis 10.1
50 myeloma, multiple 10.1

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyneuropathy:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 falls 59 32 frequent (33%) Frequent (79-30%) HP:0002527
2 paresthesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003401
3 areflexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001284
4 difficulty walking 59 32 frequent (33%) Frequent (79-30%) HP:0002355
5 fatiguable weakness of proximal limb muscles 59 32 hallmark (90%) Very frequent (99-80%) HP:0030200
6 difficulty climbing stairs 59 32 frequent (33%) Frequent (79-30%) HP:0003551
7 unsteady gait 59 32 hallmark (90%) Very frequent (99-80%) HP:0002317
8 segmental peripheral demyelination/remyelination 59 32 hallmark (90%) Very frequent (99-80%) HP:0003481
9 sensory ataxia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010871
10 motor conduction block 59 32 hallmark (90%) Very frequent (99-80%) HP:0012078
11 hand muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0030237
12 spontaneous pain sensation 59 32 occasional (7.5%) Occasional (29-5%) HP:0010833
13 peripheral neuropathy 59 Very frequent (99-80%)
14 decreased nerve conduction velocity 59 Very frequent (99-80%)
15 peripheral demyelination 59 Very frequent (99-80%)
16 sensory impairment 59 Very frequent (99-80%)
17 abnormal nerve conduction velocity 59 Very frequent (99-80%)

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Not Applicable
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9 tannic acid Approved Phase 3
10
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
11
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
12 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
13 Fingolimod Hydrochloride Phase 3
14 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
15 Hormone Antagonists Phase 3,Phase 1,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
17 glucocorticoids Phase 3,Phase 1,Phase 2
18 Hormones Phase 3,Phase 1,Phase 2
19 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
20 Pharmaceutical Solutions Phase 3,Phase 2
21
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
22
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
23
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
24
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
25
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
26
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
27
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
28
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
29
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
32 Antioxidants Phase 2
33 Vitamin B9 Phase 2
34 Vitamins Phase 2
35 Protective Agents Phase 2,Phase 1
36 Thioctic Acid Phase 2
37 Trace Elements Phase 2
38 Alpha-lipoic Acid Phase 2
39 Folate Phase 2
40 Vitamin B Complex Phase 2
41 Micronutrients Phase 2
42 Interferon-beta Phase 2
43 Antiviral Agents Phase 2
44 Anti-Infective Agents Phase 2
45 Adjuvants, Immunologic Phase 2,Phase 1
46 interferons Phase 2
47 Antirheumatic Agents Phase 1, Phase 2,Phase 2
48 Gastrointestinal Agents Phase 1, Phase 2
49 Methylprednisolone acetate Phase 1, Phase 2
50 Krestin Phase 1, Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
7 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
10 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
11 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
12 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
13 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
16 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
17 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
18 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
19 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
20 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
21 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
22 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
23 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
24 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
25 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
26 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
27 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
28 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
29 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
30 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
31 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
32 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
33 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
34 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
35 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
36 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
37 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
38 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
39 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
40 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
41 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
42 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
43 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022 Not Applicable
44 Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Recruiting NCT03656640 Gammanorm
45 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
46 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
47 Transcriptome Analysis of the Peripheral Blood in CIDP Active, not recruiting NCT02404298 Not Applicable IVIg
48 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Not Applicable Standard of Care
49 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890 Not Applicable
50 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

41
T Cells, Bone, Spinal Cord, Skin, B Cells, Thyroid, Heart

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50) (show all 638)
# Title Authors Year
1
Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 30266626 )
2019
2
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
3
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
4
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
5
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
6
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
7
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
8
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
9
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
10
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
11
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
12
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
13
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
14
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
15
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
16
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
17
High-resolution nerve ultrasound and magnetic resonance neurography as complementary neuroimaging tools for chronic inflammatory demyelinating polyneuropathy. ( 29552093 )
2018
18
Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance. ( 29867996 )
2018
19
Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? ( 29603302 )
2018
20
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
21
Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials. ( 29700616 )
2018
22
Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation. ( 30038356 )
2018
23
Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. ( 28345260 )
2018
24
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
25
Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. ( 29541543 )
2018
26
Reductions in muscle quality and quantity in chronic inflammatory demyelinating polyneuropathy patients assessed by magnetic resonance imaging. ( 29742800 )
2018
27
Hereditary neuropathy with liability to pressure palsies mimicking chronic inflammatory demyelinating polyneuropathy. ( 30017102 )
2018
28
Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression. ( 30027593 )
2018
29
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy. ( 30028899 )
2018
30
Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. ( 30073683 )
2018
31
Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. ( 30128319 )
2018
32
Nerve ultrasound can distinguish chronic inflammatory demyelinating polyneuropathy from demyelinating diabetic sensorimotor polyneuropathy. ( 30145079 )
2018
33
Assessing the benefit of treatment in chronic inflammatory demyelinating polyneuropathy: the challenges of clinical practice. ( 30223714 )
2018
34
Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis. ( 30240176 )
2018
35
Nerve Ultrasound, Electrophysiological, and Clinical Changes in Treatment-Naive Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 30260816 )
2018
36
Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients. ( 30293110 )
2018
37
Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. ( 30312032 )
2018
38
The economic burden and managed care implications of chronic inflammatory demyelinating polyneuropathy. ( 30312033 )
2018
39
Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines? ( 30326184 )
2018
40
New onset psoriasis in a patient with chronic inflammatory demyelinating polyneuropathy treated with Rituximab. ( 30350559 )
2018
41
Missed diagnosis of chronic inflammatory demyelinating polyneuropathy in a patient with cervical myelopathy due to ossification of posterior longitudinal ligament. ( 30370039 )
2018
42
Clinical, Sonographic, and Electrophysiologic Longitudinal Features of Chronic Inflammatory Demyelinating Polyneuropathy. ( 30407676 )
2018
43
Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy. ( 30449785 )
2018
44
Depression with Chronic Inflammatory Demyelinating Polyneuropathy. ( 30533957 )
2018
45
Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. ( 30538665 )
2018
46
Incomplete intestinal obstruction as an initial and persistent presentation in chronic inflammatory demyelinating polyneuropathy: A case report. ( 30544461 )
2018
47
Presence of both anti-contactin 1 and anti-neurofascin 140 antibodies in a case of chronic inflammatory demyelinating polyneuropathy. ( 30547099 )
2018
48
Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP). ( 30554264 )
2018
49
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. ( 30556098 )
2018
50
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

Expression for Chronic Inflammatory Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.11 CNTN2 NFASC
2
Show member pathways
10.72 CNTN2 NFASC

GO Terms for Chronic Inflammatory Demyelinating Polyneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.96 CNTN2 NFASC
2 node of Ranvier GO:0033268 8.62 CNTN2 NFASC

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.26 CNTN2 NFASC
2 defense response GO:0006952 9.16 HP IFNA2
3 neutrophil degranulation GO:0043312 9.13 HP NFASC TTR
4 protein localization to juxtaparanode region of axon GO:0071205 8.62 CNTN2 NFASC

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....